Guidelines for national programmes and other stakeholders
Annexes for webposting and CD-Rom distribution with the policy guidelines
Q2: For people with dementia, does memantine, when compared to placebo/comparator, produce benefits/harm in the specified outcomes in non-specialist health settings?
Original text from 2008, updated in 2012. This document marks the beginning of a structured approach to safety assessment of GE foods, which are yet to be approved in our country. It is understood that many changes will become necessary and will be incorporated as we progress. This document will ho...wever, remain an important milestone in the process towards safety evaluation of food derived from GE plants in India.
more
The objective of this book is to provide health workers with easily accessible information on important aspects of the medicines commonly used at primary care level in Zimbabwe. Medicines are a crucial part of the management of most of our patients, yet many medicines are potentially dangerous if no...t used correctly (by either prescriber or patient). It is important to have up-to-date information not only on the indications for, and the dose of a particular medicine, but also the contra-indications and reasons for special care, possible side effects and interactions with other medicine or medicines. The patient must also have information on how to use the preparation, what side effects may occur, and when to return for help.
more
Guidelines for national programmes and other stakeholders, for annexes see http://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/
Inclusive Project Cycle Management
Examen du rôle de la société civile dans le plaidoyer et le lobbying en faveur de l'application de la politique de santé au Kenya
African Population Studies Vol 25, 1 (Supplement) 2011
http://aps.journals.ac.za
TEP UP Technical Working Paper
Statistical Report | No. 39: 2013
CBDRR Practice. Case Studies 4
No publication year indicated.
Participant Manual September 2012
Surveillance of Populations at High Risk for HIV Transmission
J Pharm Pharm Sci (www.cspsCanada.org) 16(3) 441 - 455, 2013